Genentech's Faricimab Improved, Maintained Vision In Two Causes Of Vision Loss

Genentech, a member of the Roche Group (RHHBY), Monday announced that The Lancet has published two papers highlighting one-year results from four pivotal Phase III studies of faricimab, an investigational bispecific antibody, in wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).

All four studies - which enrolled more than 3,000 people in total - met their primary endpoints, showing that patients treated with faricimab up to every four months achieved non-inferior vision gains compared to aflibercept, given every two months.

About half of eligible faricimab patients were able to go four months between treatments in the first year, and approximately three-quarters could go three months or longer in the Tenaya and Lucerne wet AMD studies and the Yosemite and Rhine DME studies. The current standard of care for these potentially blinding conditions requires eye injections as often as once a month.

"These data published in The Lancet reinforce the potential of faricimab as an important treatment option that may help improve and maintain vision while extending the time between treatments up to four months," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We remain deeply committed to developing new medicines such as faricimab that may help preserve sight in many people living with serious retinal conditions."

If approved, faricimab would be the first bispecific antibody for the eye, targeting and inhibiting two distinct pathways linked to a number of vision-threatening retinal conditions by neutralizing angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Inhibition of both pathways has been shown to have complementary benefits, stabilizing vessels and thereby reducing vessel leakage and inflammation more than inhibition of the VEGF-A pathway alone.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared... Richmond, Utah-based Casper's Ice Cream is recalling its 56 ounce tubs of "Red Button Vintage Creamery Canadian Vanilla Ice Cream" due to undeclared allergen, the U.S. Food and Drug Administration said. According to the agency, a limited number of the product were mispackaged with Burnt Almond Fudge Ice Cream containing undeclared almonds.
Follow RTT